Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.
Therapeutic vaccination has been proposed as a strategy to augment immune mechanisms to control viral replication and slow clinical progression of HIV infection to disease. Following recombinant gp160 (r-gp160) immunization in three clinical trials, plasma HIV-1 RNA and cellular proviral DNA were assessed by quantitative polymerase chain reaction (PCR) in 76 HIV-seropositive subjects with CD4+ T cell counts > or = 300/mm3. Immunization increased HIV-specific cellular immune responses (e.g., cytotoxic T lymphocyte [CTL] activities, lymphocyte proliferative responses); however, there were no significant effects of immunization or cellular immune responses on measures of plasma RNA or cellular DNA viral load.
Kundu
S K
SK
Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, U.S.A.
Katzenstein
D
D
Valentine
F T
FT
Spino
C
C
Efron
B
B
Merigan
T C
TC
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy* / Q000821:virology; D000328:Adult; D018791:CD4 Lymphocyte Count; D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D008297:Male; D008875:Middle Aged; D011533:Proviruses / Q000235:genetics*; D012367:RNA, Viral / Q000097:blood*; D012795:Sialoglycoproteins / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D016915:AIDS Vaccines; D004279:DNA, Viral; D012367:RNA, Viral; D012795:Sialoglycoproteins; D014614:Vaccines, Synthetic